ProFound AI
Discover the ProFound impact of world-class artificial intelligence for digital breast tomosynthesis
FDA Cleared, CE Marked, Health Canada Licensed
ProFound AI™
for Digital Breast Tomosynthesis
Brochure
Request a demo
Press Release
White Paper
Podcast
Formerly branded as PowerLook Tomo Detection 2.0
FDA Cleared, CE Marked, Health Canada Licensed
A reading revolution in tomosynthesis has arrived.
The difference is ProFound.
The high-performing, concurrent-read, cancer detection and workflow solution rapidly analyzes each tomosynthesis image accurately, detecting both malignant soft tissue densities and calcifications with unrivaled accuracy.
Built on the latest deep-learning and artificial intelligence technology, ProFound AI for breast tomosynthesis is clinically proven to assist radiologists in addressing the challenges of reading tomosynthesis cases by:
- Improving cancer detection rates
- Reducing false positives and unnecessary patient recalls
- Decreasing reading times
Compatible with leading digital breast tomosynthesis systems
Clinical Performance Benefits
- 8.0% average increase in sensitivity
- 6.9% average increase in specificity
- 7.2% average reduction in recalls
- 5.7% average improvement in radiologist AUC
Workflow Benefits
- 52.7% reduction in reading time
- Certainty of Finding scores assist in prioritizing caseload and clinical decision-making
Customer Spotlight: RMI
Randy Hicks, M.D., MBA, radiologist, co-owner and CEO at Regional Medical Imaging shares his excitement and discusses the value ProFound AI provides to his facility and patients.
ProFound AI™ for Digital Breast Tomosynthesis Technology
Rodney Hawkins, vice president of marketing, iCAD Inc. discusses how ProFound AI assists in the interpretation of breast tomosynthesis exams with exceptional reader study results.
Certainty of Finding and Case Scores
The ProFound AI algorithm is trained to detect malignant soft tissue densities and calcifications. Certainty of Finding and Case Scores are assigned to each detection and each case respectively. Certainty of Finding and Case Scores are relative scores computed by the ProFound AI algorithm and represent the algorithm’s confidence that a detection or case is malignant. The scores are represented on a 0% to 100% scale. A higher score indicates a higher level of confidence in the malignancy of the detection or case. The scores are calibrated to a population of 50% prevalence of cancer and should be interpreted as the probability of the detection or case correctly being identified as malignant in a population of 50% cancers and 50% non-cancers. The Certainty of Finding and Case Scores serve as a guide to the interpreting radiologist to aid in determining if a suspicious finding or case needs further workup.
Certainty of Finding Score
Certainty of Finding Scores are assigned to each detection identified by the ProFound AI algorithm. The Certainty of Finding Score represents how confident the algorithm is that the detection is malignant.
Case Score
Case Scores are assigned to each case by the ProFound AI algorithm. The Case Score represents how confident the algorithm is that a case is malignant. All cases, including those without detections, will be assigned a Case Score.
Platform
ProFound AI for digital breast tomosynthesis runs on the industry-leading PowerLook server platform with NVIDIA Graphical Processing Units (GPU). PowerLook is a flexible and reliable DICOM platform that easily integrates with image modalities, mammography review workstations, PACS, and image storage systems. Leveraging the latest in GPU technology, the algorithm can rapidly process a 4-view tomosynthesis case, ensuring results are available to radiologists in the most efficient manner.
Resources
Client Case Study
Press Releases
iCAD’s ProFound AI Joins Nuance AI Marketplace for Diagnostic Imaging
iCAD’s ProFound AI Wins “Best New Radiology Solution” in 2019 MedTech Breakthrough Awards
iCAD Announces FDA Clearance of ProFound AI™ for Digital Breast Tomosynthesis
Request a Product Demo
Related Articles
EurekAlert! Radiological Society of North America
AI improves efficiency and accuracy of digital breast tomosynthesis
HPR
The Role of 3D Mammography on Radiologist Burnout
Dr. Jeffrey Hoffmeister, MD, VP, Medical Director at iCAD, Inc
Forbes
2018's Biggest Moments In AI (Artificial Intelligence)
Diagnostic Imaging Europe
AI breast tomosynthesis in a dynamic private radiology practice
Axel Gräwingholt, MD – Paderborn, Germany
Medical Device and Diagnostic Industry
iCAD’s AI Solution Has Exceptional Results in Study
Precise and Powerful Healthcare Solutions
© 2019, iCAD Inc. All rights reserved. iCAD, the iCAD logo,, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.